Scholar Rock wins FDA OK for first SMA muscle drug — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Scholar Rock received FDA approval on Friday for Isembyld, the first-ever therapy to target muscle loss in spinal muscular atrophy, a rare neurological disorder
- Isembyld is approved for adults and children 2 years and older who are already receiving SMA therapies that target SMN2, the key gene for motor-controlling neurons
- A late-stage clinical trial found that combining Isembyld with an SMN2-targeting drug improved young patients' motor skills after a year, while the placebo group's skills declined — a statistically significant difference
- Scholar Rock CEO David Hallal called the approval "a defining moment for the SMA community" in a press release, framing it as a breakthrough after decades of industry-wide failures to unlock myostatin inhibition
- The approval positions Isembyld as an add-on to existing SMA drugs (Spinraza, Evrysdi, Zolgensma), all of which address the underlying neuronal cause but do not directly target muscle preservation
Why it matters: For SMA patients already on SMN2-targeting therapies, Isembyld adds the first FDA-approved option that addresses muscle wasting itself rather than only the neuronal cause — the statistically significant motor improvement versus placebo decline in the late-stage trial gives Scholar Rock a defensible first-mover position in an add-on market no competitor has yet entered.
Ask SkimNews
